Search results
Showing 76 to 90 of 169 results for asthma
Our indicators measure outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
Health inequalities can be experienced by people grouped by a range of different factors.
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.
This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.
This quality standard covers diagnosing, assessing and treating community-acquired and hospital-acquired pneumonia in babies over 1 month (corrected gestational age), children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover ventilator associated pneumonia or COVID-19 pneumonia.
View quality statements for QS110Show all sections
Sections for QS110
weeks choosing between medical or surgical abortion before 14 weeks asthma inhalers and climate change should I stop my benzodiazepine...
Older people with social care needs and multiple long-term conditions (NG22)
This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.
O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)
NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).
This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).